Olink

Olink®
Part of Thermo Fisher Scientific

Filters

PublicationDisease areaApplication areaSample typeProducts

Molecular Cancer Therapeutics, 2015
The Tyrosine Kinase Inhibitors Imatinib and Dasatinib Reduce Myeloid Suppressor Cells and Release Effector Lymphocyte Responses

Christiansson L., Söderlund S., Mangsbo S. et al.

Olink Target 96OncologyTechnology EvaluationPlasma

Frontiers in Neurology, 2014
Cerebral Microdialysis for Protein Biomarker Monitoring in the Neurointensive Care Setting – A Technical Approach

Hillered L., Dahlin A., Clausen F. et al.

NeurologyTechnology Evaluation

Arteriosclerosis, Thrombosis, and Vascular Biology, 2014
High Plasma Levels of Heparin-Binding Epidermal Growth Factor Are Associated With a More Stable Plaque Phenotype and Reduced Incidence of Coronary Events

Rattik S., Wigren M., Björkbacka H. et al.

Olink Target 96CVDPatient StratificationPlasma

Brain, Behavior, and Immunity, 2014
Increased cerebrospinal fluid interleukin-8 in bipolar disorder patients associated with lithium and antipsychotic treatment

Isgren A., Jakobsson J., Pålsson E. et al.

Olink Target 96NeurologyTechnology EvaluationSerumCSF

International Orthopaedics, 2014
Exogenous BMP7 corrects plasma iron overload and bone loss in Bmp6-/- mice

Pauk M., Grgurevic L., Brkljacic J. et al.

Olink Target 96Other Diseases & SyndromesPathophysiologySerum

Nature Communications, 2014
Strong effects of genetic and lifestyle factors on biomarker variation and use of personalized cutoffs

Enroth S., Johansson ?., Enroth S. et al.

Olink Target 96OncologyEpidemiologyPlasma

PLoS ONE, 2014
Homogenous 96-Plex PEA Immunoassay Exhibiting High Sensitivity, Specificity, and Excellent Scalability

Assarsson E., Lundberg M., Holmquist G. et al.

PROTEOMICS, 2014
Antibody‐based proteomics and biomarker research—Current status and limitations

Solier C., Langen H.

Technical StudiesTechnology Evaluation

4488 publications